Abstract:Introduction: The study of the pathophysiology study of Alzheimer's disease (AD) has been hampered by lack animal models that recapitulate the major AD pathologies, including extracellular -amyloid (A) deposition, intracellular aggregation of microtubule associated protein tau (MAPT), inflammation and neurodegeneration. Methods: The humanized APP NL-G-F knock-in mouse line was crossed to the PS19 MAPT P301S , over-expression mouse line to create the dual APPNL-G-F/PS19 MAPTP301S line. The resulting pathologies were characterized by immunochemical methods and PCR. Results: We now report on a double transgenic APP NL-G-F /PS19 MAPT P301S mouse that at 6 months of age exhibits robust A plaque accumulation, intense MAPT pathology, strong inflammation and extensive neurodegeneration. The presence of A pathology potentiated the other major pathologies, including MAPT pathology, inflammation and neurodegeneration. MAPT pathology neither changed levels of amyloid precursor protein nor potentiated A accumulation. Interestingly, study of immunofluorescence in cleared brains indicates that microglial inflammation was generally stronger in the hippocampus, dentate gyrus and entorhinal cortex, which are regions with predominant MAPT pathology. The APP NL-G-F /MAPT P301S mouse model also showed strong accumulation of N 6 -methyladenosine (m 6 A), which was recently shown to be elevated in the AD brain. m 6 A primarily accumulated in neuronal soma, but also co-localized with a subset of astrocytes and microglia. The accumulation of m 6 A corresponded with increases in METTL3 and decreases in ALKBH5, which are enzymes that add or remove m6A from mRNA, respectively. Discussion: Our understanding of the pathophysiology of Alzheimer's disease (AD) has been hampered by lack animal models that recapitulate the major AD pathologies, including extracellular -amyloid (A) deposition, intracellular aggregation of microtubule associated protein tau (MAPT), inflammation and neurodegeneration. The APP NL-G-F /MAPT P301S mouse recapitulates many features of AD pathology beginning at 6 months of aging, and thus represents a useful new mouse model for the field. Graphical . This figure summarizes the pathophysiological changes occurring in the APP NL-G-F /MAPT P301S mouse model. This model has the humanized APP NL-G-F gene as a knocking. The neurons consequently produce abundant Aβ 40/42 which leads to rapid formation of extracellular Aβ plaques. The accumulation of Aβ stimulates inflammation and also feeds back to neurons to enhance MAPT pathology and neurodegeneration. The neurons over-express P301S MAPT, which leads to rapid formation of MAPT pathologies; the amount of pathology is enhanced modestly by the abundant production and aggregation of Aβ. The MAPT aggregation in the neurons stimulate the accumulation of cytoplasmic m 6 A, presumably as part of the translational stress response. Secreted MAPT stimulates microglial inflammation and astrocytosis. All of these factors accelerate neurodegeneration. The inflammation in this model tends to accumulate most in regions with MAPT pathology, particularly the hippocampus, although some reactive microglia are also observed near Aβ plaques.

Neuronal loss and microgliosis are restricted to the core of Aβ deposits in mouse models of Alzheimer's disease

Microglia limit the expansion of β-amyloid plaques in a mouse model of Alzheimer's disease

The Effect of Chronic Cerebral Hypoperfusion on Amyloid-β Metabolism in a Transgenic Mouse Model of Alzheimer's Disease (PS1V97L).

Brain region-specific myelinogenesis is not directly linked to amyloid-β in APP/PS1 transgenic mice

Loss of Cholinergic and Monoaminergic Afferents in APPswe/PS1ΔE9 Transgenic Mouse Model of Cerebral Amyloidosis Preferentially Occurs near Amyloid Plaques

Microglia contributes to plaque growth by cell death due to uptake of amyloid β in the brain of Alzheimer's disease mouse model

Tau Accumulation Induces Microglial State Alterations in Alzheimer's Disease Model Mice

Beta-Secretase-1 Elevation In Transgenic Mouse Models Of Alzheimer'S Disease Is Associated With Synaptic/Axonal Pathology And Amyloidogenesis: Implications For Neuritic Plaque Development

Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer’s disease mouse model with suppression of glymphatic clearance

Preferential clustering of microglia and astrocytes around neuritic plaques during progression of Alzheimer's disease neuropathological changes

Β‐secretase‐1 Elevation in Transgenic Mouse Models of Alzheimer’s Disease is Associated with Synaptic/axonal Pathology and Amyloidogenesis: Implications for Neuritic Plaque Development

Brain region‐specific amyloid plaque‐associated myelin lipid loss, APOE deposition and disruption of the myelin sheath in familial Alzheimer’s disease mice

Humanized Tau Mice with Regionalized Amyloid Exhibit Behavioral Deficits but No Pathological Interaction

Neuronal activity regulates the regional vulnerability to amyloid-β deposition

Β-Amyloid Accumulation Enhances Microtubule Associated Protein Tau Pathology in an APPNL-G-F/MAPTP301S Mouse Model of Alzheimer’s Disease

Nanoscale Reorganisation of Synaptic Proteins in Alzheimer's Disease

β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer's disease

Investigation of the Subcellular Neurotoxicity of Amyloid‐β Using a Device Integrating Microfluidic Perfusion and Chemotactic Guidance

Neurodegenerative Changes Associated with β-Amyloid Deposition in the Brains of Mice Carrying Mutant Amyloid Precursor Protein and Mutant Presenilin-1 Transgenes

Functional Deprivation Promotes Amyloid Plaque Pathogenesis in Tg2576 Mouse Olfactory Bulb and Piriform Cortex.

Amyloid-β plaques disrupt axon initial segments